Melbourne Internal Medicine Associates (MIMA) Treats Metastatic Cancer Using Ultra-Precise Image-Guided Radiotherapy Technology From Varian Medical Systems
Posted on: Tuesday, 14 March 2006, 09:01 CST
MELBOURNE, Fla., March 14 /PRNewswire-FirstCall/ -- Doctors at Melbourne Internal Medical Associates (MIMA) Cancer Center have treated a metastatic liver tumor with ultra-precise image-guided radiotherapy using new technology from Varian Medical Systems. The MIMA IGRT system is equipped with Varian's On-Board Imager(TM) device for positioning patients with sub-millimeter accuracy.
The 64-year-old male patient had been treated a year earlier for lung cancer, along with a solitary brain metastasis. He subsequently lived for almost a year with no sign of cancer, according to Todd Scarbrough, MD, radiation oncologist and director of the MIMA Cancer Center. Then, in a routine surveillance scan, MIMA radiologists spotted a metastatic lesion in the patient's liver.
"We had three choices," Scarbrough said. "We could do nothing. We could treat him with chemotherapy. Or we could use our new image-guided radiotherapy technology to deliver a very high dose of radiation directly to the tumor in what's known as a 'radiosurgical' treatment. With radiosurgery, we deliver very high doses of radiation in just one or a few treatment sessions. This requires us to target the lesion very precisely, compensate for any tumor motion, and do all we can to protect the surrounding healthy tissues."
In the past, radiosurgical procedures have been used primarily to treat tumors in the brain, because the head can be effectively immobilized, which renders brain tumors motionless and facilitates accurate targeting. "Body radiosurgery is a new procedure, made possible by technologies like the On-Board Imager, which helps us ensure that our treatment beams accurately hit the tumor," Scarbrough said.
To position their patient for treatment, Scarbrough and his clinical team utilized two of the imaging modalities available with the On-Board Imager: radiographic kV X-ray imaging, and three-dimensional cone-beam CT imaging.
"Prior to each treatment, we used the On-Board Imager to take orthogonal X-ray images of the liver and used them to calculate how to shift the patient to make sure the tumor was lined up precisely with the treatment beam," Scarbrough said. "We were amazed at how well the liver showed up on the radiographic X-ray images. We could see enough detail to make the necessary positioning corrections. We then generated a three-dimensional cone-beam CT image as a check, to verify that our calculations were correct in all three dimensions."
To address the problem of tumor motion due to respiration, MIMA clinicians used a CT scanner outfitted with Varian's RPM(TM) respiratory gating technology to generate the images used in treatment planning. "This enabled us to choose the optimal point in the patient's respiratory cycle for delivering each treatment," said Joseph Ting, PhD, chief medical physicist at the MIMA Cancer Center.
The novel radiosurgical procedure involved three treatments delivered every other day over a five-day period.
"Our goal was to see if we could eradicate the liver lesion using a method that has essentially zero toxicity, sparing him the more toxic effects of chemotherapy," Scarbrough said. "The treatment was administered four weeks ago. The patient is doing great and has suffered no side effects. A CT scan in early March showed that the liver lesion had regressed dramatically. It is too early to say what the long-term results will be, but we're very hopeful."
Virtually all cancer patients treated with conformal radiation therapy at MIMA now receive image-guided treatments. "We use every tool at our disposal to set up the patient more accurately for treatment," said Ting. "With IGRT, we are very confident we're targeting the right place."
ABOUT MELBOURNE INTERNAL MEDICINE ASSOCIATES (MIMA)
MIMA an independent, physician-owned multispecialty group offering patients comprehensive medical care throughout Brevard County, Florida. Comprised of over 100 physicians representing 23 medical specialties, MIMA's board-certified physicians provide high-quality medical care at 15 locations on Florida's Space Coast. The MIMA Cancer Center's Department of Radiation Oncology treats 80-90 patients per day, and has been offering image-guided radiotherapy (IGRT) using technology from Varian Medical Systems since April 2005. For further information, visit http://www.mima.com/.
ABOUT VARIAN MEDICAL SYSTEMS
Varian Medical Systems, Inc., of Palo Alto, California is the world's leading manufacturer of integrated cancer therapy systems, which are treating thousands of patients per day. The company is also a premier supplier of X- ray tubes and flat-panel digital subsystems for imaging in medical, scientific, and industrial applications. Varian Medical Systems employs approximately 3,500 people who are located at manufacturing sites in North America and Europe and in its 56 sales and support offices around the world. Additional information is available on the company's web site at http://www.varian.com/ .
FOR INFORMATION CONTACT: Spencer Sias, 650-424-5782 spencer.sias@varian.com Meryl Ginsberg, 650-424-6444 meryl.ginsberg@varian.com
Varian Medical Systems, Inc.
CONTACT: Spencer Sias, +1-650-424-5782, or spencer.sias@varian.com; orMeryl Ginsberg, +1-650-424-6444, or meryl.ginsberg@varian.com, both of Varian
Web site: http://www.varian.com/http://www.mima.com/
Source: PRNewswire-FirstCall
Related Articles
- Finding The Effective Pain Treatment For Cancer Patients
- PTC Therapeutics Initiates Two Clinical Trials of PTC299 in Cancer Patients
- Clinicians in Netherlands Treat Lung Cancer Patients Using New RapidArc Radiotherapy Technology From Varian Medical Systems
- Sirtex Supports the Fourth Annual Clinical Symposium on Liver-Directed Microsphere Therapy Dedicated to Advancing Treatments for Patients With Inoperable Metastatic Liver Cancer
- New Non-Invasive Treatment Option for Lung Cancer Patients Offered By CyberKnife Center of Miami
- Advanced Capabilities of BSD Medical's New Cancer Ablation System Unveiled at International Engineering Conference
- Cancer Patients in Western Australia to Benefit From New Treatments Using Latest Equipment From Varian Medical Systems
- FDA Grants Intracel Special Protocol Assessment (SPA) for Confirmatory, Pivotal Phase III Study of OncoVAX(R) Colon Cancer Vaccine; OncoVAX(R) Vaccine Designed to Prevent Recurrence in Stage II Colon Cancer Patients Following Surgical Tumor Resection
- Large Community-Based Clinical Trial in Older Cancer Patients Suggests Benefits of Neulasta in First and Subsequent Cycles Of Chemotherapy
User Comments (0)

RSS Feeds